Skip to main content

Exicure, Inc.

corporate_fare Company Profile

Exicure, Inc.

XCUR·NASDAQ·Life Sciences·CIK 0001698530

The company, historically an early-stage biotechnology firm, focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, it significantly reduced its workforce, suspended preclinical activities, and halted all research and development. In February 2024, the company received an upfront payment of $500,000 from a licensing agreement for patents related to one of its historical drug candidates, along with a small, one-time payment and an entitlement to modest future royalties. In the second quarter of 2024, it recognized other income of $637,000 from the sale of samples related to the licensed product. In the third quarter of 2024, the company sold its historical biotechnology intellectual property and other assets, including the aforementioned licensing agreement, recognizing other income of $1,500,000. Any future value from these historical assets will primarily come from royalties and license fees under this purchase agreement, though these are uncertain. The company is actively exploring strategic alternatives, including private company acquisitions, raising additional capital, and strategic partnerships. On January 19, 2025, the company acquired all issued and outstanding equity securities of GPCR Therapeutics USA Inc., a California corporation, from GPCR Therapeutics Inc., a Korean corporation.

Exicure, Inc. (NASDAQ:XCUR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 30 items for XCUR at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Exicure Issues Going Concern Warning as Cash Dips to $3.7M for FY2025
  • Exicure Appoints New CEO and Interim CFO, Filling Key Leadership Vacancies
  • Exicure Announces CEO, CFO Resignations and Major Board Overhaul
  • Exicure Achieves Phase 2 Clinical Milestone for Stem Cell Mobilizer, Triggers $1M Payment and Enhanced Sublicensing Terms
  • Major Shareholder Exicure HiTron Inc. Reduces Stake in EXICURE, INC.

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$0
Net Income
-$4.95M
Diluted EPS
-$0.79
Op. Cash Flow
-$8.55M
Free Cash Flow
-$8.56M
Operating Income
-$4.23M
Cash & Equivalents
$3.75M
Debt / Equity
0.00×
Shares Outstanding
6.37M sh
Source: 10-K · filed 2026-03-25 · accession 0001698530-26-000028
$0.9905 +1.07% today
52-week range · as of 2026-11-20 $0.777 – $9.48
Market cap
$5.89M
Volume
32.1K (0.4× avg)
3-mo avg 73.2K
Live data · 2026-11-22 12:55 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed XCUR - Filings & News (Page 2)

XCUR
Mar 25, 2026, 4:18 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $4.61
Real-time Price: $0.9905 info
Change: -$3.62 (-79%) info
Market Cap: $5.892M info
XCUR
Feb 17, 2026, 5:25 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.81
Real-time Price: $0.9905 info
Change: -$2.82 (-74%) info
Market Cap: $5.892M info
XCUR
Feb 10, 2026, 4:25 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.31
Real-time Price: $0.9905 info
Change: -$3.32 (-77%) info
Market Cap: $5.892M info
XCUR
Jan 22, 2026, 4:29 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.43
Real-time Price: $0.9905 info
Change: -$5.44 (-85%) info
Market Cap: $5.892M info
XCUR
Jan 21, 2026, 1:21 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $6.10
Real-time Price: $0.9905 info
Change: -$5.11 (-84%) info
Market Cap: $5.892M info
XCUR
Jan 21, 2026, 12:46 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $6.10
Real-time Price: $0.9905 info
Change: -$5.11 (-84%) info
Market Cap: $5.892M info
XCUR
Jan 20, 2026, 5:48 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $6.14
Real-time Price: $0.9905 info
Change: -$5.15 (-84%) info
Market Cap: $5.892M info
XCUR
Jan 20, 2026, 2:09 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $6.14
Real-time Price: $0.9905 info
Change: -$5.15 (-84%) info
Market Cap: $5.892M info
XCUR
Jan 09, 2026, 8:09 AM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $5.76
Real-time Price: $0.9905 info
Change: -$4.77 (-83%) info
Market Cap: $5.892M info
XCUR
Jan 08, 2026, 8:42 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $5.88
Real-time Price: $0.9905 info
Change: -$4.89 (-83%) info
Market Cap: $5.892M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets